Vedolizumab has been studied in 2,700 patients in nearly 40 different countries. It is designed to treat moderate to severe Crohn’s disease and ulcerative colitis.
More Articles on Gastroenterology:
MIT Researchers Develop 3-D Colonoscopy Technique
Florida Medical Association Names Dr. Alan Harmon President
New York Gastroenterology Associates Opens Scarsdale Office
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
